Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Lucy Wortham James Basic Research Award: Markers of Prostatic Carcinoma

Lucy Wortham James Basic Research Award: Markers of Prostatic Carcinoma Abstract • Markers of human prostatic cancer are important diagnostic aids in the management of this most common tumor among US men. A rapidly expanding body of basic and clinical knowledge about the properties and behavior of these unique organ-specific macromolecules bridges the gap between sophisticated immunochemistry and everyday practice. As a consequence, the patient benefits, because greater opportunities for early detection of prostatic cancer provide more freedom in selecting the most effective treatment modalities. Parallel improvement in quantitative assessment of an existing tumor mass allows earlier and more precise monitoring of the positive therapeutic responses and/or disease progression, as well as better overall prognosis. In addition, marker molecules can provide specific targets for antibodydirected therapeutic compounds active against prostatic cancer. This study focused on three such markers: prostatic acid phosphatase, prostate-specific antigen, and a new membrane-associated marker defined by a monoclonal antibody called 7E11-C5. A critical evaluation of clinical usefulness and prospects for future developments are presented. (Arch Surg. 1991;126:1404-1407) References 1. Boring CC, Squires TS, Tong T. Cancer statistics . CA . 1991;41:19-38. 2. Murphy GP, Natarajan N, Pontes JE, et al. The national survey of prostate cancer in the United States by the American College of Surgeons . J Urol . 1982;127:928-934. 3. Makuch RW, Muenz LR. Evaluating the adequacy of tumor markers to discriminate among distinct populations . Semin Oncol . 1987;14:89-101. 4. Gutman EB, Sproul EE, Gutman AB. Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland . Am J Cancer . 1936;28:485-495.Crossref 5. Gutman AB, Gutman EB. An 'acid' phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland . J Clin Invest . 1938;17:473-478.Crossref 6. Huggins C, Scott WW, Hodges CV. Studies on prostatic cancer, Ill: the effects of fever, desoxycorticosterone, and of estrogen on clinical patients with metastatic carcinoma of the prostate . J Urol . 1941;46:997-1006. 7. Murphy GP, Reynoso G, Kenny GM, GaetaJF. Comparison of total and prostatic fraction serum acid phosphatase levels in patients with differentiated and undifferentiated prostatic carcinoma . Cancer . 1969;23:1309-1314.Crossref 8. Shulman S, Mamrod L, Gonder MJ, Soanes WA. The detection of prostatic acid phosphatase by antibody reactions in gel diffusion . J Immunol . 1964;93:474-479. 9. Lin MF, Lee CL, Wojcieszyn JW, et al. Fundamental biochemical and immunological aspects of prostatic acid phosphatase . Prostate . 1980;1:415-425.Crossref 10. Nguyen L, Chapdelaine A, Chevalier S. Prostatic acid phosphatase in serum of patients with prostatic cancer is a specific phosphotyrosine acid phosphatase . Clin Chem . 1990;36:1450. 11. Chu TM, Wang MC, Scott WW, et al. Immunochemical detection of serum prostatic acid phosphatase . Invest Urol . 1978;15:319-323. 12. Catane R, Madajewicz S, Wajsman ZL, et al. Prostatic cancer: immunochemical detection of prostatic acid phosphatase in serum and bone marrow . N Y State J Med . 1978;78:1060-1061. 13. Murphy GP, Karr J, Chu TM. Prostatic acid phosphatase: where are we? CA . 1978;28:258-264. 14. Lee C, Wang MC, Murphy GP, Chu TM. A solid-phase fluorescent immunoassay for human prostatic acid phosphatase . Cancer Res . 1978;38:2871-2878. 15. Wajsman Z, Lee C, Chu TM, Murphy GP. A new fluorescent immunoassay for human prostatic acid phosphatase in prostate cancer (SPIF) . Surg Forum . 1979;30:568-569. 16. Wajsman Z, Chu TM, Saroff J, Slack N, Murphy GP. Two new, direct, and specific methods of acid phosphatase determination . Urology . 1979;13:8-11.Crossref 17. Lee CL, Chu TM, Wajsman LZ, Slack NH, Murphy GP. Value of new fluorescent immunoassay for human prostatic acid phosphatase in prostate cancer . Urology . 1980;15:338-341.Crossref 18. Killian CS, Vargas FP, Slack NH, Murphy GP, Chu TM. Prostate-specific acid phosphatase versus acid phosphatase in monitoring patients with prostate cancer . Ann N Y Acad Sci . 1982;380:122-132.Crossref 19. Heller JE. Prostatic acid phosphatase: its current clinical status . J Urol . 1987;137:1091-1103. 20. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purifications of a human prostate specific antigen . Invest Urol . 1979;17:159-163. 21. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients . Cancer Res . 1980;40:2428-2432. 22. Papsidero LD, Kuriyama M, Wang MC, et al. Prostate antigen: a marker for human prostate epithelial cells . JNCI . 1981;66:37-42. 23. Nadji M, Tabei SZ, Castro A, et al. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms . Cancer . 1981;48:1229-1232.Crossref 24. Kuriyama M, Wang MC, Lee C, et al. Use of human prostate-specific antigen in monitoring prostate cancer . Cancer Res . 1981;41:3874-3876. 25. Kuriyama M, Wang MC, Lee CL, et al. Multiple marker evaluation in human prostate cancer with the use of tissuespecific antigens . J Natl Cancer Inst . 1982;68:99-105. 26. Pontes JE, Chu TM, Slack N, Karr J, Murphy GP. Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course . J Urol . 1982;128:1216-1218. 27. Sensabaugh GF, Blake ET. Seminal plasma protein p30: simplified purification and evidence for identity with prostate specific antigen . J Urol . 1990;144:1523-1526. 28. Lundwall A. Characterization of the gene for prostatespecific antigen, a human glandular kallikrein . Biochem Biophys Res Commun . 1989;161:1151-1159.Crossref 29. Warhol MJ, Longtine JA. The ultrastructural localization of prostate specific antigen and prostatic acid phosphatase in hyperplastic and neoplastic human prostates . J Urol . 1985;134:607-613. 30. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate . N Engl J Med . 1987;317:909-916.Crossref 31. Mannini D, Maver P, Aiello E, et al. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer . Urol Res . 1988;16:9-12.Crossref 32. Graves HB, Wehner N, Stamey TA. Comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international antigen standard . J Urol . 1990;144:1516-1522. 33. Lange PH. Prostatic specific antigen in diagnosis and management of prostate cancer . Urology . 1990;36( (suppl) ):25-29.Crossref 34. Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, I: untreated patients . J Urol . 1989;141:1070-1075. 35. Brawer MK, Lange PH. Prostate-specific antigen and premalignant change: implications for early detection . CA . 1989;39:361-375. 36. Pontes JE, Jabalameli P, Montie J, et al. Prognostic implications of disappearance rate of biologic markers following radical prostatectomy . Urology . 1990;34:415-419.Crossref 37. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, II: radical prostatectomy treated patients . J Urol . 1989;141:1076-1083. 38. Stamey TA, Kabalin JN, Ferrari M. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, III: radiation treated patients . J Urol . 1989;141:1084-1087. 39. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, IV: anti-androgen treated patients . J Urol . 1989;141:1088-1090. 40. Leroy M, Teillac P, Rain JD, et al. Radioimmunodetection of lymph node invasion in prostate cancer . Cancer . 1989;64:1-5.Crossref 41. Babaian RJ, Lamki LM. Radioimmunoscintigraphy of prostate cancer . Semin Nucl Med . 1989;19:309-321.Crossref 42. Meyers FJ, Denardo SJ, Macey D, White RD, Unger M. Development of monoclonal antibody imaging of metastatic prostatic carcinoma . Prostate . 1989;14:209-220.Crossref 43. Horoszewicz JS, Murphy GP. Prospective new developments in laboratory research and clinical trials in prostatic cancer . Cancer . 1990;66( (suppl) ):1083-1085. 44. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients . Anticancer Res . 1987;7:927-936. 45. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCap model of human prostatic carcinoma . Cancer Res . 1983;43:1809-1819. 46. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5 . Cancer Res . 1990;50:6423-6429. 47. Wynat GE, Murphy GP, Horoszewicz JS, et al. Immunoscintigraphy of prostatic cancer: preliminary results with 111 In-labeled monoclonal antibody 7E11-C5.3 (CYT-356) . Prostate . 1991;18:229-241.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Lucy Wortham James Basic Research Award: Markers of Prostatic Carcinoma

Archives of Surgery , Volume 126 (11) – Nov 1, 1991

Loading next page...
 
/lp/american-medical-association/lucy-wortham-james-basic-research-award-markers-of-prostatic-carcinoma-2aqGLCFEne
Publisher
American Medical Association
Copyright
Copyright © 1991 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1991.01410350098014
Publisher site
See Article on Publisher Site

Abstract

Abstract • Markers of human prostatic cancer are important diagnostic aids in the management of this most common tumor among US men. A rapidly expanding body of basic and clinical knowledge about the properties and behavior of these unique organ-specific macromolecules bridges the gap between sophisticated immunochemistry and everyday practice. As a consequence, the patient benefits, because greater opportunities for early detection of prostatic cancer provide more freedom in selecting the most effective treatment modalities. Parallel improvement in quantitative assessment of an existing tumor mass allows earlier and more precise monitoring of the positive therapeutic responses and/or disease progression, as well as better overall prognosis. In addition, marker molecules can provide specific targets for antibodydirected therapeutic compounds active against prostatic cancer. This study focused on three such markers: prostatic acid phosphatase, prostate-specific antigen, and a new membrane-associated marker defined by a monoclonal antibody called 7E11-C5. A critical evaluation of clinical usefulness and prospects for future developments are presented. (Arch Surg. 1991;126:1404-1407) References 1. Boring CC, Squires TS, Tong T. Cancer statistics . CA . 1991;41:19-38. 2. Murphy GP, Natarajan N, Pontes JE, et al. The national survey of prostate cancer in the United States by the American College of Surgeons . J Urol . 1982;127:928-934. 3. Makuch RW, Muenz LR. Evaluating the adequacy of tumor markers to discriminate among distinct populations . Semin Oncol . 1987;14:89-101. 4. Gutman EB, Sproul EE, Gutman AB. Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland . Am J Cancer . 1936;28:485-495.Crossref 5. Gutman AB, Gutman EB. An 'acid' phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland . J Clin Invest . 1938;17:473-478.Crossref 6. Huggins C, Scott WW, Hodges CV. Studies on prostatic cancer, Ill: the effects of fever, desoxycorticosterone, and of estrogen on clinical patients with metastatic carcinoma of the prostate . J Urol . 1941;46:997-1006. 7. Murphy GP, Reynoso G, Kenny GM, GaetaJF. Comparison of total and prostatic fraction serum acid phosphatase levels in patients with differentiated and undifferentiated prostatic carcinoma . Cancer . 1969;23:1309-1314.Crossref 8. Shulman S, Mamrod L, Gonder MJ, Soanes WA. The detection of prostatic acid phosphatase by antibody reactions in gel diffusion . J Immunol . 1964;93:474-479. 9. Lin MF, Lee CL, Wojcieszyn JW, et al. Fundamental biochemical and immunological aspects of prostatic acid phosphatase . Prostate . 1980;1:415-425.Crossref 10. Nguyen L, Chapdelaine A, Chevalier S. Prostatic acid phosphatase in serum of patients with prostatic cancer is a specific phosphotyrosine acid phosphatase . Clin Chem . 1990;36:1450. 11. Chu TM, Wang MC, Scott WW, et al. Immunochemical detection of serum prostatic acid phosphatase . Invest Urol . 1978;15:319-323. 12. Catane R, Madajewicz S, Wajsman ZL, et al. Prostatic cancer: immunochemical detection of prostatic acid phosphatase in serum and bone marrow . N Y State J Med . 1978;78:1060-1061. 13. Murphy GP, Karr J, Chu TM. Prostatic acid phosphatase: where are we? CA . 1978;28:258-264. 14. Lee C, Wang MC, Murphy GP, Chu TM. A solid-phase fluorescent immunoassay for human prostatic acid phosphatase . Cancer Res . 1978;38:2871-2878. 15. Wajsman Z, Lee C, Chu TM, Murphy GP. A new fluorescent immunoassay for human prostatic acid phosphatase in prostate cancer (SPIF) . Surg Forum . 1979;30:568-569. 16. Wajsman Z, Chu TM, Saroff J, Slack N, Murphy GP. Two new, direct, and specific methods of acid phosphatase determination . Urology . 1979;13:8-11.Crossref 17. Lee CL, Chu TM, Wajsman LZ, Slack NH, Murphy GP. Value of new fluorescent immunoassay for human prostatic acid phosphatase in prostate cancer . Urology . 1980;15:338-341.Crossref 18. Killian CS, Vargas FP, Slack NH, Murphy GP, Chu TM. Prostate-specific acid phosphatase versus acid phosphatase in monitoring patients with prostate cancer . Ann N Y Acad Sci . 1982;380:122-132.Crossref 19. Heller JE. Prostatic acid phosphatase: its current clinical status . J Urol . 1987;137:1091-1103. 20. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purifications of a human prostate specific antigen . Invest Urol . 1979;17:159-163. 21. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients . Cancer Res . 1980;40:2428-2432. 22. Papsidero LD, Kuriyama M, Wang MC, et al. Prostate antigen: a marker for human prostate epithelial cells . JNCI . 1981;66:37-42. 23. Nadji M, Tabei SZ, Castro A, et al. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms . Cancer . 1981;48:1229-1232.Crossref 24. Kuriyama M, Wang MC, Lee C, et al. Use of human prostate-specific antigen in monitoring prostate cancer . Cancer Res . 1981;41:3874-3876. 25. Kuriyama M, Wang MC, Lee CL, et al. Multiple marker evaluation in human prostate cancer with the use of tissuespecific antigens . J Natl Cancer Inst . 1982;68:99-105. 26. Pontes JE, Chu TM, Slack N, Karr J, Murphy GP. Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course . J Urol . 1982;128:1216-1218. 27. Sensabaugh GF, Blake ET. Seminal plasma protein p30: simplified purification and evidence for identity with prostate specific antigen . J Urol . 1990;144:1523-1526. 28. Lundwall A. Characterization of the gene for prostatespecific antigen, a human glandular kallikrein . Biochem Biophys Res Commun . 1989;161:1151-1159.Crossref 29. Warhol MJ, Longtine JA. The ultrastructural localization of prostate specific antigen and prostatic acid phosphatase in hyperplastic and neoplastic human prostates . J Urol . 1985;134:607-613. 30. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate . N Engl J Med . 1987;317:909-916.Crossref 31. Mannini D, Maver P, Aiello E, et al. Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer . Urol Res . 1988;16:9-12.Crossref 32. Graves HB, Wehner N, Stamey TA. Comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international antigen standard . J Urol . 1990;144:1516-1522. 33. Lange PH. Prostatic specific antigen in diagnosis and management of prostate cancer . Urology . 1990;36( (suppl) ):25-29.Crossref 34. Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, I: untreated patients . J Urol . 1989;141:1070-1075. 35. Brawer MK, Lange PH. Prostate-specific antigen and premalignant change: implications for early detection . CA . 1989;39:361-375. 36. Pontes JE, Jabalameli P, Montie J, et al. Prognostic implications of disappearance rate of biologic markers following radical prostatectomy . Urology . 1990;34:415-419.Crossref 37. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, II: radical prostatectomy treated patients . J Urol . 1989;141:1076-1083. 38. Stamey TA, Kabalin JN, Ferrari M. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, III: radiation treated patients . J Urol . 1989;141:1084-1087. 39. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, IV: anti-androgen treated patients . J Urol . 1989;141:1088-1090. 40. Leroy M, Teillac P, Rain JD, et al. Radioimmunodetection of lymph node invasion in prostate cancer . Cancer . 1989;64:1-5.Crossref 41. Babaian RJ, Lamki LM. Radioimmunoscintigraphy of prostate cancer . Semin Nucl Med . 1989;19:309-321.Crossref 42. Meyers FJ, Denardo SJ, Macey D, White RD, Unger M. Development of monoclonal antibody imaging of metastatic prostatic carcinoma . Prostate . 1989;14:209-220.Crossref 43. Horoszewicz JS, Murphy GP. Prospective new developments in laboratory research and clinical trials in prostatic cancer . Cancer . 1990;66( (suppl) ):1083-1085. 44. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients . Anticancer Res . 1987;7:927-936. 45. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCap model of human prostatic carcinoma . Cancer Res . 1983;43:1809-1819. 46. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5 . Cancer Res . 1990;50:6423-6429. 47. Wynat GE, Murphy GP, Horoszewicz JS, et al. Immunoscintigraphy of prostatic cancer: preliminary results with 111 In-labeled monoclonal antibody 7E11-C5.3 (CYT-356) . Prostate . 1991;18:229-241.Crossref

Journal

Archives of SurgeryAmerican Medical Association

Published: Nov 1, 1991

References